James S Blachly, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI’m an oncologist focused on the treatment of patients diagnosed with hairy cell leukemia, acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). I’m a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James and serve as an assistant professor in The Ohio State University Division of Hematology. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics. My work explores whether and how mutations and transcriptional attributes can be studied in the context of clinical trials to provide prognostic and predictive information relevant to novel anticancer therapies. I was recently named as one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation. I received a six-figure grant for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.” I love the collaborative spirit at OSUCCC – James and how we all share the common purpose of providing optimal and effective care and treatment for patients –– and the goal of one day living in a world free of cancer.
Clinical Expertise
More info for- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Acute Myeloid Leukemias
- Hairy Cell Leukemia
- Chronic Lymphocytic Leukemias
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia
Research Interests
More info for- Thyroid Neoplasms
- Infection
- Neoplasms
- Carcinoma, Non-Small Cell Lung
- Leukemia, Hairy Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lung Neoplasms
- Hemorrhage
- Melanoma
- Exanthema
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Medical School
- University of Arkansas College of Medicine
4301 West Markham St, Little Rock, AR
Internship - Internal Medicine
- University of Arkansas for Medical Sciences
4301 W Markham St, Little Rock, AR
Residency - Internal Medicine
- University of Arkansas for Medical Sciences
4301 W Markham St, Little Rock, AR
- Ohio State University Wexner Medical Center
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0481C
410 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-5667Email:
blachly.3@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 4, 2024Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mrózek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK
Nat Genet
October 1, 2024Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Kapoor N, Zhao Q, Stiff A, Bhat SA, Anghelina MI, Andritsos LA, Blachly JS, Epperla N, Boghdadly ZE, Grever MR, Rogers KA
EJHaem
September 16, 2024White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.
Ozga M, Nicolet D, Mrózek K, Walker CJ, Blachly JS, Kohlschmidt J, Orwick S, Carroll AJ, Larson RA, Kolitz JE, Powell BL, Stone RM, Byrd JC, Eisfeld AK, Mims AS
Am J Hematol
August 21, 2024A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.
Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Andrade-Campos M, Kadia TM, Blachly JS
Clin Cancer Res
August 9, 2024Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM
J Clin Oncol
June 8, 2024Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani PL
Leukemia
March 4, 2024The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR, Halpin M, Corbin DL, Asemelash Y, Sher S, Gordon BK, Whipp EC, Mitchell S, Harrington BK, Orwick S, Benrashid S, Goettl VM, Yildiz V, Mitchell AD, Cahn O, Mims AS, Larkin KTM, Long M, Blachly J, Woyach JA, Lapalombella R, Grieselhuber NR
Exp Hematol Oncol
January 12, 2024Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC
Blood
November 28, 2023Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AK
Leukemia
November 1, 2023Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.
Annunzio K, Ozga M, Huang Y, Anghelina M, Bhat SA, Blachly JS, Grever MR, Lozanski G, Neal J, Shindiapina P, Rogers KA
EJHaem
September 4, 2023Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R
Leuk Lymphoma
August 22, 2023Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JC
Blood Adv
May 18, 2023Microenvironmental control of hematopoietic stem cell fate via CXCL8 and protein kinase C.
Binder V, Li W, Faisal M, Oyman K, Calkins DL, Shaffer J, Teets EM, Sher S, Magnotte A, Belardo A, Deruelle W, Gregory TC, Orwick S, Hagedorn EJ, Perlin JR, Avagyan S, Lichtig A, Barrett F, Ammerman M, Yang S, Zhou Y, Carson WE, Shive HR, Blachly JS, Lapalombella R, Zon LI, Blaser BW
Cell Rep
May 17, 2023Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
Rebechi M, Kohlschmidt J, Mrózek K, Nicolet D, Mims AS, Blachly JS, Orwick S, Larkin K, Oakes CC, Hantel A, Carroll AJ, Blum W, Powell BL, Uy GL, Stone RM, Larson RA, Byrd JC, Paskett ED, Plascak JJ, Eisfeld AK
Blood Adv
February 1, 2023Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center.
Freeman T, Williams K, Puto M, Waller A, McLaughlin EM, Blachly JS, Roddy J
World J Oncol
January 6, 2023Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R
Nat Commun
December 13, 2022Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M
Blood Cancer J
November 14, 2022VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R
Leukemia
November 9, 2022Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.
Montgomery EJ, Xing E, Campbell MJ, Li PK, Blachly JS, Tsung A, Coss CC
Int J Mol Sci
October 26, 2022HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia.
Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos JJ, Shukla SA, Puduvalli VK, Woyach JA, Lapalombella R, Blachly JS, Byrd JC, Sampath D
Blood Adv
September 16, 2022Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions.
Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, Walker JS, Canfield D, Beaver L, Cempre CB, Phillips H, Chen X, Yan P, Lehman A, Scherle P, Wang M, Vaddi K, Baiocchi R, Wang R, Sampath D, Alinari L, Blachly JS, Lapalombella R
Sci Adv
September 7, 2022Development of a distributed international patient data registry for hairy cell leukemia.
Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M
Leuk Lymphoma
September 2, 2022Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].
Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA
Leuk Res
September 1, 2022Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.
Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA
Leuk Res
July 7, 2022BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.
Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD, Blaser BW
Blood Adv
July 5, 2022High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
Larkin K, Nicolet D, Kelly BJ, Mrózek K, LaHaye S, Miller KE, Wijeratne S, Wheeler GL, Kohlschmidt J, Blachly JS, Mims AS, Walker C, Oakes CC, Orwick S, Boateng I, Buss J, Heyrosa A, Desai H, Carroll AJ, Blum W, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Paskett ED, Byrd JC, Mardis E, Eisfeld AK
Blood Adv
March 28, 2022Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication.
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui CH, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD
Clin Cancer Res
March 1, 2022Challenges and Gaps in Clinical Trial Genomic Data Management.
Asad S, Kananen K, Mueller KR, Symmans WF, Wen Y, Perou CM, Blachly JS, Chen J, Vincent BG, Stover DG
JCO Clin Cancer Inform
November 30, 2021Molecular associations, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia (Alliance).
Fobare S, Kohlschmidt J, Ozer HG, Mrózek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd JC
Blood Adv
November 3, 2021Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.
Walker JS, Hing ZA, Sher S, Cronin J, Williams K, Harrington B, Skinner JN, Cempre CB, Gregory CT, Pan A, Yano M, Beaver LP, Walker BR, Labanowska JM, Heerema NA, Mrózek K, Woyach JA, Ruppert AS, Lehman A, Ozer HG, Coppola V, Yan P, Byrd JC, Blachly JS, Lapalombella R
Nat Commun
October 28, 2021Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR
Hematol Oncol
June 23, 2021A precision medicine classification for treatment of acute myeloid leukemia in older patients.
Mims AS, Kohlschmidt J, Borate U, Blachly JS, Orwick S, Eisfeld AK, Papaioannou D, Nicolet D, Mr?zek K, Stein E, Bhatnagar B, Stone RM, Kolitz JE, Wang ES, Powell BL, Burd A, Levine RL, Druker BJ, Bloomfield CD, Byrd JC
J Hematol Oncol
May 21, 2021Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS
Leukemia
May 4, 2021Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, Call T, Cross M, Dearden C, Demeter J, Dietrich S, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Juliusson G, Kraut E, Kreitman RJ, Lauria F, Lozanski G, Parikh SA, Park J, Polliack A, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Zent C, Zenz T, Zinzani PL, Wörmann B
Leukemia
March 24, 2021Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C
Am J Hematol
March 22, 2021Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
Rogers KA, Andritsos LA, Wei L, McLaughlin E, Ruppert AS, Anghelina M, Blachly JS, Call TG, Chihara D, Dauki AM, Guo L, Ivy SP, James L, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps MA, Ravandi F, Schiffer C, Carson Iii WE, Jones JA, Grever MR
Blood
March 11, 2021DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.
Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC
Genome Res
February 4, 2021Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Lai TH, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R
Clin Cancer Res
December 4, 2020Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.
Bhatnagar B, Kohlschmidt J, Mrózek K, Zhao Q, Fisher JL, Nicolet D, Walker CJ, Mims AS, Oakes C, Giacopelli B, Orwick S, Boateng I, Blachly JS, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Byrd JC, Paskett ED, de la Chapelle A, Garzon R, Eisfeld AK
Cancer Discov
December 3, 2020TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY, Buelow DR, Garrison DA, Niu M, Eisenmann ED, Huang KM, Zavorka Thomas ME, Weber RH, Whatcott CJ, Warner SL, Orwick SJ, Carmichael B, Stahl E, Brinton LT, Lapalombella R, Blachly JS, Hertlein E, Byrd JC, Bhatnagar B, Baker SD
JCI Insight
December 1, 2020Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts.
Gregory T, Ngankeu A, Orwick S, Kautto EA, Woyach JA, Byrd JC, Blachly JS
NAR Genom Bioinform
October 19, 2020Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, Wasmuth R, Beaver L, Cempre C, Skinner J, Cannon M, Govande M, Harrington B, Lehman A, Byrd JC, Lapalombella R, Blachly JS
J Hematol Oncol
October 5, 2020Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.
Bill M, Mrózek K, Kohlschmidt J, Eisfeld AK, Walker CJ, Nicolet D, Papaioannou D, Blachly JS, Orwick S, Carroll AJ, Kolitz JE, Powell BL, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD
Proc Natl Acad Sci U S A
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
August 20, 2020Entospletinib in Combination With Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 expression.
Walker A, Byrd JC, Blachly JS, Bhatnagar B, Mims A, Orwick S, Lin TL, Crosswell HE, Zhang D, Minden MD, Munugalavadla V, Long L, Liu J, Pan Y, Oellerich T, Serve H, Rao AV, Blum WG
Clin Cancer Res
August 10, 2020A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS
Am J Hematol
August 5, 2020Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
Mims AS, Kohlschmidt J, Eisfeld AK, Mr?zek K, Blachly JS, Orwick S, Papaioannou D, Nicolet D, Sampath D, Stone RM, Powell BL, Kolitz JE, Byrd JC, Bloomfield CD
Leukemia
June 18, 2020LC-FACSeq is a method for detecting rare clones in leukemia.
Hu EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang CL, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, Byrd JC
JCI Insight
June 14, 2020Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.
Brinton LT, Sher S, Williams K, Canfield D, Orwick S, Wasmuth R, Cempre C, Skinner J, Lehman A, Blachly JS, Byrd JC, Lapalombella R
Cancers (Basel)
May 27, 2020Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK, Kohlschmidt J, Mims A, Nicolet D, Walker CJ, Blachly JS, Carroll AJ, Papaioannou D, Kolitz JE, Powell BE, Stone RM, de la Chapelle A, Byrd JC, Mrózek K, Bloomfield CD
Leukemia
March 24, 2020Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz AS, Rogers KA, Byrd J, Woyach JA, Blachly JS
Blood
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Blachly has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- University of North Carolina at Chapel Hill
- Hairy Cell Leukemia Foundation
- Syndax
- European School of Hematology
- Gnosigen LLC
Patient Comments
Dr. Blachly is great at both my physical health as well as my mental health. Truly cares for his patients.
Dr. Blachly is an outstanding physician with excellent patient interaction skills.
We waited over an hour to see Dr. Blachly and he spent about 10+ minutes with us.
Although I had to wait longer than expected to see Dr. Blachly and the genetic counselor's expertise were worth the wait. They spent an extended period of time with me and Dr. Blachly even drew diagrams for me to better understand my condition. He talked about the role of family and culture in terms of the rarity of my genetic anomoly. They were very thorough.
Very good
Dr. Blachly makes my husband and I feel like we are the most important people he sees. Dr. Bixel and Walls are empathic and always give me direction and all my OSU doctors communicate with my doctors at MVH.
Dr. Blachly is an outstanding physician in every respect.
I would say OUTSTANDING rather than Very Good
Dr. Blachley and his staff are excellent.
Already provided.
Just wish he wouldn't compare me to every other patient when i'm explaining what i'm going through and what side effects that I may be experiencing. My body doesn't react the same as everyone else's
Doctor answered all my questions.
Good
Very good.
Dr. Blachley is always informative and caring. Answers all concerns and questions and shows care and concern.
Dr. James Blachly spends as much time needed & truly cares for the patient.
Dr. Blachley & Ben are excellent. Five star service